Brokerages expect Core Laboratories (NYSE:CLB) to post sales of $171.85 million for the current quarter, according to Zacks. Two analysts have issued estimates for Core Laboratories’ earnings, with the highest sales estimate coming in at $172.16 million and the lowest estimate coming in at $171.54 million. Core Laboratories reported sales of $149.54 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 14.9%. The firm is scheduled to announce its next quarterly earnings report after the market closes on Wednesday, January 31st.

On average, analysts expect that Core Laboratories will report full-year sales of $171.85 million for the current year, with estimates ranging from $656.10 million to $660.12 million. For the next year, analysts expect that the firm will report sales of $731.16 million per share, with estimates ranging from $719.09 million to $750.74 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Core Laboratories.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings data on Monday, October 23rd. The oil and gas company reported $0.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.04. Core Laboratories had a net margin of 12.06% and a return on equity of 52.89%. The business had revenue of $166.20 million during the quarter, compared to analyst estimates of $160.94 million. During the same period in the prior year, the business earned $0.38 EPS. The company’s revenue for the quarter was up 1.4% on a year-over-year basis.

Several brokerages recently issued reports on CLB. Deutsche Bank lowered shares of Core Laboratories from a “buy” rating to a “hold” rating and decreased their price target for the stock from $116.30 to $109.00 in a research note on Thursday, January 11th. Zacks Investment Research lowered shares of Core Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. ABN Amro lowered shares of Core Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Scotiabank set a $136.00 price target on shares of Core Laboratories and gave the stock a “hold” rating in a research note on Wednesday, October 25th. Finally, Royal Bank of Canada reiterated a “buy” rating on shares of Core Laboratories in a research note on Wednesday, October 18th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company. Core Laboratories presently has a consensus rating of “Hold” and a consensus price target of $110.20.

A number of hedge funds have recently made changes to their positions in CLB. Schwab Charles Investment Management Inc. grew its position in Core Laboratories by 6.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 139,549 shares of the oil and gas company’s stock valued at $14,133,000 after purchasing an additional 8,774 shares during the last quarter. CIBC World Markets Inc. purchased a new stake in Core Laboratories during the 2nd quarter valued at about $223,000. Eaton Vance Management grew its position in Core Laboratories by 46.4% during the 2nd quarter. Eaton Vance Management now owns 21,852 shares of the oil and gas company’s stock valued at $2,213,000 after purchasing an additional 6,924 shares during the last quarter. Alliancebernstein L.P. grew its position in Core Laboratories by 18.0% during the 2nd quarter. Alliancebernstein L.P. now owns 2,942 shares of the oil and gas company’s stock valued at $298,000 after purchasing an additional 448 shares during the last quarter. Finally, Nationwide Fund Advisors grew its position in Core Laboratories by 27.6% during the 2nd quarter. Nationwide Fund Advisors now owns 7,881 shares of the oil and gas company’s stock valued at $798,000 after purchasing an additional 1,705 shares during the last quarter.

Core Laboratories (CLB) opened at $117.45 on Thursday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.18 and a quick ratio of 1.81. The company has a market cap of $5,200.56, a price-to-earnings ratio of 67.50 and a beta of 1.56. Core Laboratories has a 1-year low of $86.55 and a 1-year high of $124.99.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 16th. Investors of record on Friday, January 26th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 1.87%. The ex-dividend date is Thursday, January 25th. Core Laboratories’s dividend payout ratio (DPR) is 126.44%.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Core Laboratories (CLB) Will Announce Quarterly Sales of $171.85 Million” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/18/zacks-analysts-anticipate-core-laboratories-clb-will-announce-quarterly-sales-of-171-85-million.html.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Get a free copy of the Zacks research report on Core Laboratories (CLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.